A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics and Efficacy of Isatuximab in Combination With Cemiplimab in Patients With Relapsed/Refractory Multiple Myeloma
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs Cemiplimab (Primary) ; Isatuximab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 12 Jul 2019 Planned End Date changed from 1 Mar 2021 to 1 Apr 2020.
- 12 Jul 2019 Planned primary completion date changed from 1 Mar 2021 to 1 Apr 2020.
- 12 Jul 2019 Status changed from recruiting to active, no longer recruiting.